Happy Thanksgiving? Super Committee Failure Offers Respite For Biopharma
This article was originally published in The Pink Sheet Daily
Executive Summary
The congressional Joint Select Committee on Deficit Reduction’s inability to agree on a plan to cut $1.2 trillion from the federal deficit over 10 years offers a best-case scenario for the biopharmaceutical industry, at least in the near-term.
You may also be interested in...
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.
Biden vs Trump On Drug Pricing And Unfinished Business
While more significant reforms are less likely under a second Biden term unless Democrats control both chambers of Congress, former President Trump could look to put his stamp on drug pricing reform by resurrecting one of his former policies involving international reference pricing and Medicare Part B drugs.
GSK Is Third Major Inhaler Maker To Cap Copays; Will Teva Follow?
It might make sense from a competitive standpoint for Teva to join the trend. That’s the way it happened in the insulin category.